Showing results (1781-1790 of 3,024) with videos related to
Sort By:
Pageof 303
Current Pharmaceutical Biotechnology|August 20, 2009
Reducing background contributions in fluorescence fluctuation time-traces for single-molecule measurements in solutionZeno Földes-Papp, Shih-Chu Jeff Liao, Tiefeng You, et al.Current Pharmaceutical Biotechnology|September 10, 2011
Targeting stenosis with nucleotide-hydrolyzing enzymesElzbieta Kaczmarek, Katarzyna KoziakCurrent Pharmaceutical Biotechnology|September 10, 2011
Bone tissue engineering - a field for new medicinal products?Małgorzata Lewandowska-Szumiel, Joanna WójtowiczCurrent Pharmaceutical Biotechnology|September 10, 2011
Stem cells in pharmaceutical biotechnologyEwa K Zuba-Surma, Alicja Józkowicz, Józef DulakCurrent Pharmaceutical Biotechnology|December 23, 2011
Reducing the development of antibiotic resistance in critical care unitsMarjolein P D Deege, David L PatersonCurrent Pharmaceutical Biotechnology|December 23, 2011
A novel lily-of-the-valley fragrance contrast agent for magnetic resonance and fluorescence imaging of prostate cancer cellsAlexander Sturzu, Hartmut Echner, Uwe Klose, et al.Current Pharmaceutical Biotechnology|January 31, 2012
Metabotropic glutamate receptors as targets for novel antipsychotic treatmentsL J Gray, A J Hannan, X ZhangCurrent Pharmaceutical Biotechnology|January 31, 2012
Immunological treatment options for schizophreniaNorbert Müller, Aye-Mu Myint, Markus J SchwarzCurrent Pharmaceutical Biotechnology|January 31, 2012
Innovative treatment approaches in schizophrenia enhancing neuroplasticity: aerobic exercise, erythropoetin and repetitive transcranial magnetic stimulationT Wobrock, A Hasan, P FalkaiCurrent Pharmaceutical Biotechnology|January 28, 2012
The role of an experimental model of atherosclerosis: apoE-knockout mice in developing new drugs against atherogenesisJacek JawienPageof 303